RU2126407C1 - Производные ксантина - Google Patents
Производные ксантина Download PDFInfo
- Publication number
- RU2126407C1 RU2126407C1 RU94027686/04A RU94027686A RU2126407C1 RU 2126407 C1 RU2126407 C1 RU 2126407C1 RU 94027686/04 A RU94027686/04 A RU 94027686/04A RU 94027686 A RU94027686 A RU 94027686A RU 2126407 C1 RU2126407 C1 RU 2126407C1
- Authority
- RU
- Russia
- Prior art keywords
- compound
- cells
- xanthine
- formula
- effect
- Prior art date
Links
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title claims abstract description 12
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title claims description 6
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 150000001875 compounds Chemical class 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 11
- 238000000034 method Methods 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 150000003212 purines Chemical class 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 20
- 150000003254 radicals Chemical class 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000005259 measurement Methods 0.000 description 7
- 210000003024 peritoneal macrophage Anatomy 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000002025 microglial effect Effects 0.000 description 6
- 101100018382 Shigella flexneri icsP gene Proteins 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 101150022349 sopA gene Proteins 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 108010062580 Concanavalin A Proteins 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- YWCSDTAKJJLSPO-UHFFFAOYSA-N 3-benzyl-7h-purine-2,6-dione Chemical compound O=C1NC(=O)C=2NC=NC=2N1CC1=CC=CC=C1 YWCSDTAKJJLSPO-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- -1 alkaline earth metal salts Chemical class 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229940065721 systemic for obstructive airway disease xanthines Drugs 0.000 description 2
- 0 *C(c1c(C(N2*)=O)[n](*)cc1)C2=O Chemical compound *C(c1c(C(N2*)=O)[n](*)cc1)C2=O 0.000 description 1
- YRBJELAPTBSPEP-UHFFFAOYSA-N 1-(5-hydroxy-5-methylhexyl)-3,7-dihydropurine-2,6-dione Chemical compound O=C1N(CCCCC(C)(O)C)C(=O)NC2=C1NC=N2 YRBJELAPTBSPEP-UHFFFAOYSA-N 0.000 description 1
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- SGURXVHAKRAMLJ-UHFFFAOYSA-N 3,7-dibenzyl-1-(5-hydroxy-5-methylhexyl)purine-2,6-dione Chemical compound C1=2N=CN(CC=3C=CC=CC=3)C=2C(=O)N(CCCCC(C)(O)C)C(=O)N1CC1=CC=CC=C1 SGURXVHAKRAMLJ-UHFFFAOYSA-N 0.000 description 1
- GMANCBOGUXSDSL-UHFFFAOYSA-N 3,7-dibenzylpurine-2,6-dione Chemical compound C1=NC=2N(CC=3C=CC=CC=3)C(=O)NC(=O)C=2N1CC1=CC=CC=C1 GMANCBOGUXSDSL-UHFFFAOYSA-N 0.000 description 1
- KKXZOXMBTLMNMX-UHFFFAOYSA-N 3-benzyl-7-(ethoxymethyl)-1-(5-hydroxy-5-methylhexyl)purine-2,6-dione Chemical compound O=C1N(CCCCC(C)(C)O)C(=O)C=2N(COCC)C=NC=2N1CC1=CC=CC=C1 KKXZOXMBTLMNMX-UHFFFAOYSA-N 0.000 description 1
- UNFZWROYSWYZCT-UHFFFAOYSA-N 3-benzyl-7-(ethoxymethyl)purine-2,6-dione Chemical compound O=C1NC(=O)C=2N(COCC)C=NC=2N1CC1=CC=CC=C1 UNFZWROYSWYZCT-UHFFFAOYSA-N 0.000 description 1
- HJPBXTSDJGSZRR-UHFFFAOYSA-N 6-chloro-2-methylhexan-2-ol Chemical compound CC(C)(O)CCCCCl HJPBXTSDJGSZRR-UHFFFAOYSA-N 0.000 description 1
- WDRWAQGDVCHXGX-UHFFFAOYSA-N 7-(ethoxymethyl)-1-(5-hydroxy-5-methylhexyl)-3h-purine-2,6-dione Chemical compound N1C(=O)N(CCCCC(C)(C)O)C(=O)C2=C1N=CN2COCC WDRWAQGDVCHXGX-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 210000001642 activated microglia Anatomy 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- FCYRSDMGOLYDHL-UHFFFAOYSA-N chloromethoxyethane Chemical compound CCOCCl FCYRSDMGOLYDHL-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical group 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000012760 immunocytochemical staining Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- FNEZBBILNYNQGC-UHFFFAOYSA-N methyl 2-(3,6-diamino-9h-xanthen-9-yl)benzoate Chemical compound COC(=O)C1=CC=CC=C1C1C2=CC=C(N)C=C2OC2=CC(N)=CC=C21 FNEZBBILNYNQGC-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4122884.7 | 1991-07-11 | ||
| DE4122884 | 1991-07-11 | ||
| DEP4217639.5 | 1992-05-28 | ||
| DE4217639 | 1992-05-28 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU94027686A RU94027686A (ru) | 1996-05-27 |
| RU2126407C1 true RU2126407C1 (ru) | 1999-02-20 |
Family
ID=25905369
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU94027686/04A RU2126407C1 (ru) | 1991-07-11 | 1992-07-10 | Производные ксантина |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5409935A (show.php) |
| EP (1) | EP0528164B1 (show.php) |
| JP (1) | JP3436547B2 (show.php) |
| KR (1) | KR100237945B1 (show.php) |
| AT (1) | ATE138573T1 (show.php) |
| AU (1) | AU649851B2 (show.php) |
| CA (1) | CA2073633C (show.php) |
| CZ (2) | CZ281480B6 (show.php) |
| DE (1) | DE59206403D1 (show.php) |
| DK (1) | DK0528164T3 (show.php) |
| ES (1) | ES2088519T3 (show.php) |
| GR (1) | GR3020233T3 (show.php) |
| HU (1) | HU217983B (show.php) |
| IE (1) | IE74888B1 (show.php) |
| IL (1) | IL102456A (show.php) |
| MX (1) | MX9203323A (show.php) |
| PH (1) | PH30341A (show.php) |
| RU (1) | RU2126407C1 (show.php) |
| SK (1) | SK280537B6 (show.php) |
| TW (1) | TW210285B (show.php) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2295525C2 (ru) * | 2002-06-12 | 2007-03-20 | Ф.Хоффманн-Ля Рош Аг | Амидозамещенные производные ксантина, обладающие ингибирующим действием фосфоенолпируваткарбоксикиназы (фепкк), способ их получения, фармацевтическая композиция и применение |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5648357A (en) * | 1992-03-04 | 1997-07-15 | Cell Therapeutics, Inc. | Enatiomerically pure hydroxylated xanthine compounds |
| US5567704A (en) * | 1992-03-04 | 1996-10-22 | Cell Therapeutics, Inc. | R-enatiomerically pure hydroxylated xanthine compounds to treat baldness |
| CA2112239C (en) * | 1992-03-04 | 2000-05-09 | James A. Bianco | Enantiomeric hydroxylated xanthine compounds |
| EP0570831A2 (de) * | 1992-05-20 | 1993-11-24 | Hoechst Aktiengesellschaft | Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation |
| WO1995013075A1 (en) * | 1993-11-12 | 1995-05-18 | Cell Therapeutics, Inc. | Method for preventing tissue injury from hypoxia |
| US5856330A (en) * | 1996-07-31 | 1999-01-05 | Hoechst Aktiengesellschaft | Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin |
| US5981536A (en) * | 1996-07-31 | 1999-11-09 | Hoechst Aktiengesellschaft | Use of xanthine derivatives for the modulation of apoptosis |
| IL150150A0 (en) * | 2000-01-14 | 2002-12-01 | Schering Ag | 1,2-diaryl benzimidazoles for treating illnesses associated with a microglia activation |
| US7115645B2 (en) | 2000-01-14 | 2006-10-03 | Schering Aktiengesellschaft | 1,2 diarylbenzimidazoles and their pharmaceutical use |
| US7329679B2 (en) | 2000-01-27 | 2008-02-12 | Schering Aktiengesellschaft | 1,2 Diarylbenzimidazoles and their pharmaceutical use |
| US20040110776A1 (en) * | 2002-02-22 | 2004-06-10 | Iok-Hou Pang | Use of propentofylline to control intraocular pressure |
| WO2005037286A1 (en) * | 2003-03-25 | 2005-04-28 | Vasopharm Biotech Gmbh | Use of pteridine derivatives for the treatment of increased intracranial pressure and secondary ischemia |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3328636A1 (de) * | 1982-08-10 | 1984-02-16 | Malesci S.p.A. Istituto Farmacobiologico, 50144 Firenze | Xanthinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| SU1240361A3 (ru) * | 1982-07-28 | 1986-06-23 | Адир (Фирма) | Способ получени производных ксантина |
| EP0386683A2 (en) * | 1989-03-10 | 1990-09-12 | POLI INDUSTRIA CHIMICA S.p.A. | Xanthine derivatives having bronchodilating activity, a process for the preparation thereof and pharmaceutical compositions containing them |
| EP0435811A1 (en) * | 1989-12-27 | 1991-07-03 | Laboratorios Almirall Sa | Xanthine derivatives |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2330742C2 (de) * | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| CH608236A5 (show.php) * | 1974-01-22 | 1978-12-29 | Wuelfing J A Fa | |
| US4275064A (en) * | 1976-02-06 | 1981-06-23 | Interx Research Corporation | Transient pro-drug forms of xanthine derivatives and their use as topical anti-inflammatory agents |
| US4567183A (en) * | 1983-03-11 | 1986-01-28 | Analgesic Associates | Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same |
| JPS6110715A (ja) * | 1984-06-26 | 1986-01-18 | Fanuc Ltd | 絶対位置検出方式 |
| JPH062675B2 (ja) * | 1985-04-05 | 1994-01-12 | ヘキストジヤパン株式会社 | 記憶障害治療剤 |
| DE3525801A1 (de) * | 1985-07-19 | 1987-01-22 | Hoechst Ag | Tertiaere hydroxyalkylxanthine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung |
| IT1197516B (it) * | 1986-12-24 | 1988-11-30 | Abc Ist Biolog Chem Spa | Derivati teofillinmetilanici e teofillinmetilditianici procedimento per la loro preparazione e composizioni farmaceutiche che li comprendono |
-
1992
- 1992-06-25 MX MX9203323A patent/MX9203323A/es unknown
- 1992-07-09 US US07/909,389 patent/US5409935A/en not_active Expired - Lifetime
- 1992-07-09 IL IL10245692A patent/IL102456A/en not_active IP Right Cessation
- 1992-07-09 PH PH44627A patent/PH30341A/en unknown
- 1992-07-09 HU HU9202273A patent/HU217983B/hu unknown
- 1992-07-10 CZ CS922160A patent/CZ281480B6/cs not_active IP Right Cessation
- 1992-07-10 AT AT92111761T patent/ATE138573T1/de active
- 1992-07-10 IE IE922259A patent/IE74888B1/en not_active IP Right Cessation
- 1992-07-10 CZ CZ96816A patent/CZ81696A3/cs not_active IP Right Cessation
- 1992-07-10 SK SK2160-92A patent/SK280537B6/sk not_active IP Right Cessation
- 1992-07-10 JP JP18328592A patent/JP3436547B2/ja not_active Expired - Lifetime
- 1992-07-10 ES ES92111761T patent/ES2088519T3/es not_active Expired - Lifetime
- 1992-07-10 EP EP92111761A patent/EP0528164B1/de not_active Expired - Lifetime
- 1992-07-10 DE DE59206403T patent/DE59206403D1/de not_active Expired - Lifetime
- 1992-07-10 KR KR1019920012268A patent/KR100237945B1/ko not_active Expired - Lifetime
- 1992-07-10 CA CA002073633A patent/CA2073633C/en not_active Expired - Lifetime
- 1992-07-10 RU RU94027686/04A patent/RU2126407C1/ru active
- 1992-07-10 AU AU19591/92A patent/AU649851B2/en not_active Expired
- 1992-07-10 DK DK92111761.0T patent/DK0528164T3/da active
- 1992-07-25 TW TW081105886A patent/TW210285B/zh not_active IP Right Cessation
-
1996
- 1996-06-13 GR GR960401607T patent/GR3020233T3/el unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1240361A3 (ru) * | 1982-07-28 | 1986-06-23 | Адир (Фирма) | Способ получени производных ксантина |
| DE3328636A1 (de) * | 1982-08-10 | 1984-02-16 | Malesci S.p.A. Istituto Farmacobiologico, 50144 Firenze | Xanthinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung |
| EP0386683A2 (en) * | 1989-03-10 | 1990-09-12 | POLI INDUSTRIA CHIMICA S.p.A. | Xanthine derivatives having bronchodilating activity, a process for the preparation thereof and pharmaceutical compositions containing them |
| EP0435811A1 (en) * | 1989-12-27 | 1991-07-03 | Laboratorios Almirall Sa | Xanthine derivatives |
| WO1991009859A1 (en) * | 1989-12-27 | 1991-07-11 | Laboratorios Almirall, Sa | New xanthine derivatives |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2295525C2 (ru) * | 2002-06-12 | 2007-03-20 | Ф.Хоффманн-Ля Рош Аг | Амидозамещенные производные ксантина, обладающие ингибирующим действием фосфоенолпируваткарбоксикиназы (фепкк), способ их получения, фармацевтическая композиция и применение |
Also Published As
| Publication number | Publication date |
|---|---|
| DE59206403D1 (de) | 1996-07-04 |
| HUT61763A (en) | 1993-03-01 |
| KR100237945B1 (ko) | 2000-02-01 |
| TW210285B (show.php) | 1993-08-01 |
| CZ281480B6 (cs) | 1996-10-16 |
| SK216092A3 (en) | 1995-09-13 |
| PH30341A (en) | 1997-04-02 |
| IL102456A (en) | 1996-10-16 |
| IE922259A1 (en) | 1993-01-13 |
| HU217983B (hu) | 2000-05-28 |
| MX9203323A (es) | 1994-07-29 |
| ES2088519T3 (es) | 1996-08-16 |
| EP0528164A3 (show.php) | 1994-03-02 |
| IL102456A0 (en) | 1993-01-14 |
| RU94027686A (ru) | 1996-05-27 |
| EP0528164A2 (de) | 1993-02-24 |
| AU649851B2 (en) | 1994-06-02 |
| KR930001911A (ko) | 1993-02-22 |
| HU9202273D0 (en) | 1992-10-28 |
| ATE138573T1 (de) | 1996-06-15 |
| IE74888B1 (en) | 1997-08-13 |
| CZ282140B6 (cs) | 1997-05-14 |
| EP0528164B1 (de) | 1996-05-29 |
| JP3436547B2 (ja) | 2003-08-11 |
| SK280537B6 (sk) | 2000-03-13 |
| CA2073633A1 (en) | 1993-01-12 |
| US5409935A (en) | 1995-04-25 |
| CZ81696A3 (en) | 1997-05-14 |
| JPH05186350A (ja) | 1993-07-27 |
| DK0528164T3 (da) | 1996-09-30 |
| AU1959192A (en) | 1993-01-14 |
| CZ216092A3 (en) | 1993-01-13 |
| GR3020233T3 (en) | 1996-09-30 |
| CA2073633C (en) | 2003-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60007329T2 (de) | N-heterozyklische derivate als nos inhibitoren | |
| TW577880B (en) | Novel carboxylic acid derivatives, their preparation and use | |
| DE69832715T2 (de) | Cyclin-abhängige-kinase inhibierende purinderivate | |
| FR2477542A1 (fr) | Derives de carbostyrile, leurs procedes de preparation et leur application en therapeutique | |
| JPH0826021B2 (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
| HK82292A (en) | Guanine compounds and their use for the preparation of anti-viral agents | |
| CA1276635C (en) | 9-(2-(hydroxymethyl)cycloalkylmethyl)guanines | |
| EP0389282A2 (en) | Xanthinederivatives, process for their preparation and their pharmaceutical use | |
| EP3978494A1 (en) | Methyl- and trifluoromethyl-containing disubstituted sulfonamide selective bcl-2 inhibitor | |
| IL28189A (en) | Biologically active 1-amidino-3-(substituted phenyl) ureas | |
| DK175915B1 (da) | 5-Amino- eller substituerede amino-1,2,3-triazoler anvendelige som antiproliferative midler | |
| JPH0780882B2 (ja) | ６‐チオキサンチン誘導体 | |
| IE910853A1 (en) | 2,4-pyrimidinedione derivatives and pharmaceutical compositions containing them | |
| CA1288098C (en) | 4-(guanin-9-yl)butanals and their 3-oxa, 3-thia and 2-ene derivatives having antiviral and antitumor activity | |
| CA2073633C (en) | Use of xanthine derivatives for the treatment of secondary nerve cell damage and functional disorders after cranio-cerebral traumas | |
| US4503045A (en) | 2'-Deoxy-3',5'-di-O-alkylcarbonyl-5-fluorouridine derivatives, a process for the preparation of the derivatives and anti-tumor agents containing the derivatives | |
| RU2106353C1 (ru) | Соли 5'-н-фосфоната 3'- азидо-3'-дезокситимидина, являющиеся специфическими ингибиторами продукции вируса иммунодефицита человека вич-1 и вич-2 | |
| US4060616A (en) | Purine derivatives with repeating unit | |
| US5648489A (en) | Syntheses of acyclic guanine nucleosides | |
| EP2057130A2 (en) | Improved method for synthesizing lamotrigine | |
| JPS6222771A (ja) | ５−置換−６−アミノピリミジン誘導体、組成物および使用 | |
| US5675005A (en) | Process for preparing xanthine derivatives, in particular 1,3-dipropyl-8-(3-oxocyclopentyl)-xanthine | |
| EP0074411A1 (en) | Ascorbic acid derivatives | |
| US4962114A (en) | 1-alkyl-1-sulfonyl-2-alkoxycarbonylsulfenylhydrazines having antineoplastic activity | |
| DE1795151B2 (de) | 7- eckige Klammer auf D-alpha-Amino-(3-actamidophenylacetamido) eckige Klammer zu -cephalosporansäure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PD4A | Correction of name of patent owner |